Disclosed in certain embodiments is an oral pharmaceutical dosage form comprising a pharmaceutically acceptable excipient and an effective amount of l-(3- chloro-5- {[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin- 1 -yl)thiazol-2-yl] carbamoyl} pyridin-2-yl)piperadine-4-carboxylic acid (Formula I) or a pharmaceutically acceptable salt thereof, to increase platelet levels in humans.